Barkworth

CARA in equilibrium

Short
NASDAQ:CARA   Cara Therapeutics, Inc.
Initial spike in volume was caused by fast track and phase 3 news. Nothing to drive the price at the moment. My best best is that we'll see CARA retest $19.65 within a week or so.

🅱🄰🆁🅺🆆🄾🆁🆃🅷
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.